Cardiomyopathy and Cell Therapy: Ejection Fraction Improvement and Cardiac Muscle Mass Increasing, after a Year of Bone Marrow Stem Cells Transplantation, by Magnetic Resonance ImageOswaldo Tadeu Greco1, Idiberto José Zotarelli Filho2*, Marilanda Ferreira Bellini3, Aldemir Bilaqui2, Artur Soares Souza Junior3, Milton Artur Ruiz1, Ana Carolina de Abreu1, José Luiz Balthazar Jacob2 and Adriana Barbosa Santos3
- Corresponding Author:
- Idiberto José Zotarelli Filho
Institute of Cardiovascular Diseases -
IMC - Rua Castelo D´Agua 3030 - São José do Rio Preto SP
Brazil 15015- 210
Tel: +55(17) 3203-4039; +55(17) 8166-6537
E-mail: [email protected]
Received Date: December 03, 2013; Accepted Date: December 21, 2013; Published Date: December 23, 2013
Citation: Greco OT, Filho IJZ, Bellini MF, Bilaqui A, Souza AS Junior, et al. (2013) Cardiomyopathy and Cell Therapy: Ejection Fraction Improvement and Cardiac Muscle Mass Increasing, after a Year of Bone Marrow Stem Cells Transplantation, by Magnetic Resonance Image. J Stem Cell Res Ther S6:008. doi:10.4172/2157-7633.S6-008
Copyright: © 2013 Greco OT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The idiopathic dilated cardiomyopathy (IDC) is one of the major public health problems in the western world. Patients with IDC in functional class IV (New York Health Association - NYHA), even after therapeutic optimization, have high mortality. Stem cell therapy has emerged as a potential therapeutic option for cell death-related heart diseases and several positive effects were assigned to cell therapy in cardiomyopathy. The aim of this study was identify short-term result of cell transplantation in idiopathic dilated cardiomyopathy patients (IDC) who were treated by transplantation of autologous bone marrow mononuclear cells (BMMC). Intracoronary injections of autologous BMMC were performed in eight patients with severe ventricle dysfunction (mean of left ventricle ejection fraction – LEVF=20.03%), cardiac mass muscle around 156.2 g and NYHA between III and IV grades, other 8 IDC patients received placebo. The IDCs were followed - up for one and two years, by magnetic resonance imaging (MRI). The results after one year showed significant improvement in LVEF (mean=181.4) and muscle mass increasing (mean=181.4 g), after two years the LVEF continued improving, reaching a mean of 32.69% and the cardiac muscle mass kept stable (mean=179.4 g). Excepted for one patient, all the other had improvement in the NYHA functional class. The placebo group did not show any improvement. We believe that BMMC implant may be a beneficial therapeutic option for IDC patients.